Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Results of sensitivity analyses

From: Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study

 

Multivariable Regression

HR (95% CI)

P value

Different latency Periods

  

None

  

 Binary ARBs exposure

0.95(0.78,1.15)

0.6081

 Cumulative Years of Use

0.89(0.84,0.94)

0.0001

6 months

  

 Binary ARBs exposure

0.93(0.76,1.13)

0.4524

 Cumulative Years of Use

0.93(0.90,0.96)

0.0001

1 year

  

 Binary ARBs exposure

0.95(0.77,1.16)

0.5907

 Cumulative Years of Use

0.93(0.90,0.97)

0.0002

2 years

  

 Binary ARBs exposure

0.90(0.72,1.13)

0.3744

 Cumulative Years of Use

0.94(0.91,0.98)

0.0018

ARBs vs. ACEI

  

 Binary ARBs exposure

1.33(0.85,2.08)

0.2155

 Cumulative Years of Use

0.91(0.86,0.96)

0.0009

Inverse-Probability-of-Treatment Weighting1

  

 Binary ARBs exposure

0.53(0.43,0.64)

< 0.0001

 Cumulative Years of Use

0.89(0.85,0.93)

< 0.0001

Baseline ARBs vs. non-ARBs1

  

 Binary ARBs exposure

0.74(0.57,0.95)

0.0204

 Cumulative Years of Use

0.89(0.86,0.92)

< 0.0001

  1. 1 The Cox proportional hazards model